ClinicalTrials.gg
CompletedNCT04949399Updated Nov 20, 2024Results posted

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

A Phase 3 interventional study of OnabotulinumtoxinA and Placebo in Platysma Prominence, sponsored by AbbVie. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.

Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study in the United States and Canada.

Participants will receive a single treatment of intramuscular injection of onabotulinumtoxinA (BOTOX) or placebo on Day 1 during this 4 month long study.

Participants will attend regular monthly visits during the study at the study site.

02

Conditions studied

  • Platysma Prominence

Keywords

  • Platysma Prominence
  • OnabotulinumtoxinA
  • BOTOX
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must voluntarily sign and date an , approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures
  • Are willing and able to comply with procedures required in the protocol
  • Adult male or female, at least 18 years old at the time of signing the informed consent
  • Good health as determined by medical history, physical examination, vital signs, and investigator's judgment

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
  • Anticipated need for surgery or overnight hospitalization during the study
  • Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study
  • Known immunization or to any botulinum toxin serotype
  • History of (per investigator's judgment) drug or alcohol abuse within the last 6 months
  • Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that may interfere with photography (such that photograph is not acceptable)
  • Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    BOTOX

    BOTOX (OnabotulinumtoxinA) was injected into the platysma muscle on Day 1

    Drug: OnabotulinumtoxinA

  • Placebo comparator
    Placebo

    Placebo will be injected into the platysma muscle on Day 1

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.

    Time frame: Enrollment to Day 120

  2. Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 14

    The Clinician Allergan Platysma Prominence Scale (C-APPS) evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme. The Participant Allergan Platysma Prominence Scale (P-APPS) evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

    Time frame: Day 14

  3. Achievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 14

    The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

    Time frame: Day 14

  4. Achievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self- Assessment Using P-APPS at Maximum Contraction at Day 14

    The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

    Time frame: Day 14

Secondary outcomes

  1. Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

    The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

    Time frame: Day 14, 30, 60, 90, and 120

  2. Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

    The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

    Time frame: Day 14, 30, 60, 90, and 120

  3. Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14

    The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).

    Time frame: Day 14

  4. Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 14

    The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

    Time frame: Day 14

  5. Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14

    The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

    Time frame: Day 14

  6. Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14

    The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher summary scores (range: 7-35) indicating greater negative psychosocial impact from the appearance of the neck and lower face. For change from baseline in the ANLFQ: Impacts summary score, positive values indicate worsening and negative values indicate improvement in the psychosocial impact.

    Time frame: Day 14

  7. Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

    The C-APPS evaluates platysma prominence severity and is a static measurement encompassing visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

    Time frame: Day 14, 30, 60, 90, and 120

  8. Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

    The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

    Time frame: Day 14, 30, 60, 90, and 120

  9. Percentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14

    The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

    Time frame: Day 14

  10. Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14

    The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).

    Time frame: Day 14

  11. Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 14

    The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

    Time frame: Day 14

  12. Change From Baseline on the ANLFQ: Impacts Summary Score at Days 30, 60, and 90

    The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher scores indicating greater negative impact from the appearance of the neck and lower face.

    Time frame: Days 30, 60, and 90

07

Results

Posted Nov 20, 2024

Participant flow

A total of 408 participants were enrolled and randomized in this study (199 subjects to BOTOX; 209 to placebo). A participant was considered to have completed the study if he/she had at least completed the treatment visit and the end of study visit.

Participant flow — Overall Study
MilestonePlaceboBOTOX
Started209199
Completed196190
Not completed139
Withdrew: Lost to follow-up116
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.

Time frame:
Enrollment to Day 120
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlaceboBOTOX
Number of Participants With Adverse Events4547
PrimaryComposite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 14

The Clinician Allergan Platysma Prominence Scale (C-APPS) evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme. The Participant Allergan Platysma Prominence Scale (P-APPS) evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 14
percentage of participantsPlaceboBOTOX
Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 141.9 (0.1 to 3.8)32.3 (25.7 to 38.9)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 30.4 · 95% CI 23.5 to 37.2
PrimaryAchievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 14

The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Achievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 14
percentage of participantsPlaceboBOTOX
Achievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 143.9 (1.1 to 6.8)43.8 (36.4 to 51.1)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 39.8 · 95% CI 32.0 to 47.7
PrimaryAchievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self- Assessment Using P-APPS at Maximum Contraction at Day 14

The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Achievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self- Assessment Using P-APPS at Maximum Contraction at Day 14
percentage of participantsPlaceboBOTOX
Achievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self- Assessment Using P-APPS at Maximum Contraction at Day 143.9 (1.1 to 6.8)45.6 (38.2 to 52.9)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 41.6 · 95% CI 33.7 to 49.6
SecondaryPercentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

The C-APPS evaluates platysma prominence severity and is a static measurement encompassing the investigator's visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

Time frame:
Day 14, 30, 60, 90, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120
percentage of participantsPlaceboBOTOX
Day 145.8 (2.5 to 9.2)56.9 (49.9 to 63.9)
Day 306.7 (3.3 to 10.2)44.1 (37.1 to 51.0)
Day 606.7 (3.2 to 10.2)23.8 (17.7 to 29.9)
Day 904.3 (1.4 to 7.2)11.3 (6.8 to 15.8)
Day 1201.8 (0.0 to 3.6)3.7 (1.0 to 6.4)
SecondaryPercentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

Time frame:
Day 14, 30, 60, 90, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120
percentage of participantsPlaceboBOTOX
Day 145.1 (2.1 to 8.2)51.7 (44.7 to 58.8)
Day 307.1 (3.5 to 10.7)45.1 (38.1 to 52.1)
Day 606.4 (3.0 to 9.8)33.4 (26.7 to 40.0)
Day 904.6 (1.5 to 7.7)14.7 (9.7 to 19.7)
Day 1201.6 (0.0 to 3.4)5.4 (2.2 to 8.6)
SecondaryPercentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14

The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 1411.1 (6.7 to 15.6)65.9 (59.2 to 72.6)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 54.8 · 95% CI 46.8 to 62.8
SecondaryPercentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 14

The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 1414.7 (9.6 to 19.8)53.9 (46.9 to 60.8)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 39.1 · 95% CI 30.5 to 47.8
SecondaryPercentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14

The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 147.4 (3.8 to 11.1)52.1 (45.1 to 59.1)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 44.6 · 95% CI 36.8 to 52.5
SecondaryChange From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14

The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher summary scores (range: 7-35) indicating greater negative psychosocial impact from the appearance of the neck and lower face. For change from baseline in the ANLFQ: Impacts summary score, positive values indicate worsening and negative values indicate improvement in the psychosocial impact.

Time frame:
Day 14
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14
score on a scalePlaceboBOTOX
Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14-1.7 ± 0.40-7.4 ± 0.40
Statistical analysis
  • Placebo vs BOTOX · ANCOVA · p = <.0001 (P-value derived from ANCOVA model stratified by investigator site and baseline C-APPS with baseline value as a factor.) · Difference (se): -5.7 · 95% CI -6.7 to -4.7
SecondaryPercentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

The C-APPS evaluates platysma prominence severity and is a static measurement encompassing visual examination of the platysma muscle at maximum contraction, ranging from 1 - Minimal to 5- Extreme.

Time frame:
Day 14, 30, 60, 90, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120
percentage of participantsPlaceboBOTOX
Day 1419.0 (13.5 to 24.5)80.1 (74.5 to 85.7)
Day 3021.4 (15.7 to 27.1)75.0 (68.9 to 81.1)
Day 6019.8 (14.2 to 25.4)58.5 (51.5 to 65.5)
Day 9015.0 (9.9 to 20.1)43.6 (36.5 to 50.7)
Day 1206.3 (2.8 to 9.9)21.5 (15.7 to 27.3)
SecondaryPercentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120

The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

Time frame:
Day 14, 30, 60, 90, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120
percentage of participantsPlaceboBOTOX
Day 1423.2 (17.3 to 29.1)80.5 (74.9 to 86.1)
Day 3023.2 (17.4 to 29.1)78.2 (72.5 to 84.0)
Day 6022.6 (16.8 to 28.3)69.7 (63.3 to 76.2)
Day 9020.4 (14.7 to 26.1)49.4 (42.2 to 56.6)
Day 12014.6 (9.6 to 19.6)25.8 (19.6 to 32.0)
SecondaryPercentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14

The P-APPS evaluates platysma prominence severity and is a single-item measure that is accompanied by a 5-grade photonumeric scale for participants to self-assess the severity of their platysma prominence at maximum contraction, ranging from 1 - Minimal to 5 - Extreme.

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14
percentage of participantsPlaceboBOTOX
Percentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 145.2 (1.9 to 8.5)51.4 (44.0 to 58.7)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 46.1 · 96% CI 38.1 to 54.2
SecondaryPercentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14

The ANLFQ: Satisfaction scale assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face. Item 5 is a verbal descriptor scale ranging from 1 (Very satisfied) to 5 (Very dissatisfied).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of "Satisfied" or "Very Satisfied" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 1411.7 (6.9 to 16.5)63.6 (56.5 to 70.8)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 51.9 · 95% CI 43.3 to 60.5
SecondaryPercentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 14

The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 1411.3 (6.5 to 16.2)51.5 (44.1 to 58.8)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 40.1 · 95% CI 31.3 to 49.0
SecondaryPercentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14

The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).

Time frame:
Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14
percentage of participantsPlaceboBOTOX
Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 145.4 (2.1 to 8.8)50.6 (43.3 to 58.0)
Statistical analysis
  • Placebo vs BOTOX · Cochran-Mantel-Haenszel · p = <0.0001 (P-value derived from Cochran-Mantel-Haenszel (CMH) model stratified by investigator site and baseline C-APPS.) · Difference (%): 45.2 · 95% CI 37.1 to 53.2
SecondaryChange From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14

The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher summary scores (range: 7-35) indicating greater negative psychosocial impact from the appearance of the neck and lower face. For change from baseline in the ANLFQ: Impacts summary score, positive values indicate worsening and negative values indicate improvement in the psychosocial impact.

Time frame:
Day 14
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14
score on a scalePlaceboBOTOX
Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14-2.1 ± 0.44-7.8 ± 0.43
Statistical analysis
  • Placebo vs BOTOX · ANCOVA · p = <0.0001 (P-value derived from ANCOVA model stratified by investigator site and baseline C-APPS with baseline value as a factor.) · Difference (se): -5.7 · 95% CI -6.8 to -4.6
SecondaryChange From Baseline on the ANLFQ: Impacts Summary Score at Days 30, 60, and 90

The ANLFQ: Impacts scale assesses the psychosocial impact of the appearance of the neck and lower face. All items are rated on a 5-point Verbal Descriptor Scale ranging from 1 (Never) to 5 (All of the time), with higher scores indicating greater negative impact from the appearance of the neck and lower face.

Time frame:
Days 30, 60, and 90
Reported as:
Least squares mean · score on a scale
Change From Baseline on the ANLFQ: Impacts Summary Score at Days 30, 60, and 90
score on a scalePlaceboBOTOX
Day 30-2.8 ± 0.45-8.4 ± 0.44
Day 60-2.7 ± 0.43-7.7 ± 0.43
Day 90-2.4 ± 0.45-6.3 ± 0.44
Statistical analysis
  • Placebo vs BOTOX · ANCOVA · p = <0.0001 (P-value derived from ANCOVA model stratified by investigator site and baseline C-APPS with baseline value as a factor.) · Difference (se): -5.6 · 95% CI -6.7 to -4.5
  • Placebo vs BOTOX · ANCOVA · p = <0.0001 (P-value derived from ANCOVA model stratified by investigator site and baseline C-APPS with baseline value as a factor.) · Difference (se): -5.0 · 95% CI -6.0 to -3.9
  • Placebo vs BOTOX · ANCOVA · p = <0.0001 (P-value derived from ANCOVA model stratified by investigator site and baseline C-APPS with baseline value as a factor.) · Difference (se): -3.9 · 95% CI -4.9 to -2.8

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to end of study. The median time participants were followed was 120 days for both the BOTOX and Placebo treatment groups.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/209 (0%)3/209 (1.4%)11/209 (5.3%)
BOTOX0/199 (0%)2/199 (1%)11/199 (5.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboBOTOX
APPENDICITISInfections and infestations0/2091/199
CELLULITISInfections and infestations0/2091/199
OPHTHALMIC VASCULAR THROMBOSISEye disorders1/2090/199
THYROID CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2090/199
SUBARACHNOID HAEMORRHAGENervous system disorders1/2090/199
Most frequent other events
Most frequent other events
EventPlaceboBOTOX
COVID-19Infections and infestations6/2099/199
INJECTION SITE BRUISINGGeneral disorders5/2092/199

Baseline characteristics

Baseline analyses were performed on the ITT population, consisting of all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboBOTOXTotal
Mean49.9 ± 9.7549.5 ± 10.2349.7 ± 9.98
Age, Customized
Age, Customized(Participants)PlaceboBOTOXTotal
< 40 years323264
40 - 54 years106103209
55 - 64 years6153114
≥ 65 years101121
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBOTOXTotal
Female197187384
Male121224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBOTOXTotal
Hispanic or Latino163349
Not Hispanic or Latino193166359
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBOTOXTotal
American Indian or Alaska Native000
Asian101020
Native Hawaiian or Other Pacific Islander101
Black or African American12921
White186180366
More than one race000
Unknown or Not Reported000
08

Study locations

30 sites
  • Advanced Research Associates - Glendale /ID# 229256
    Glendale, Arizona 85308, United States
  • Clear Dermatology & Aesthetics Center /ID# 229252
    Scottsdale, Arizona 85255-4134, United States
  • Clinical Testing of Beverly Hills /ID# 229946
    Encino, California 91436-2124, United States
  • Dermatology Research Associates /ID# 229949
    Los Angeles, California 90045, United States
  • Steve Yoelin MD Medical Associate Inc /ID# 229420
    Newport Beach, California 92663, United States
  • Cosmetic Laser Dermatology /ID# 229245
    San Diego, California 92121-2119, United States
  • Ava T. Shamban MD - Santa Monica. /ID# 229421
    Santa Monica, California 90404-2208, United States
  • Art of Skin MD /ID# 229255
    Solana Beach, California 92075-2228, United States
  • DMR Research PLLC /ID# 229938
    Westport, Connecticut 06880, United States
  • Susan H. Weinkle MD /ID# 229419
    Bradenton, Florida 34209-5642, United States
  • Research Institute of the Southeast, LLC /ID# 229234
    West Palm Beach, Florida 33401-2712, United States
  • Laser and Skin Surgery Center of Indiana /ID# 229515
    Indianapolis, Indiana 46260-2386, United States
  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 229414
    Metairie, Louisiana 70006, United States
  • Delricht Research /ID# 229248
    New Orleans, Louisiana 70115, United States
  • Aesthetic Center at Woodholme /ID# 229836
    Baltimore, Maryland 21208-6391, United States
  • Maryland Dermatology Laser, Skin, & Vein Institute /ID# 229260
    Hunt Valley, Maryland 21030-3216, United States
  • Image Dermatology, P.C. /ID# 229244
    Montclair, New Jersey 07042, United States
  • Laser & Skin Surgery Center of New York /ID# 229423
    New York, New York 10016-4974, United States
  • Aesthetic Solutions /ID# 229241
    Chapel Hill, North Carolina 27517-9901, United States
  • Wilmington Dermatology Center /ID# 229246
    Wilmington, North Carolina 28403, United States
  • Aventiv Research Dublin /ID# 229254
    Dublin, Ohio 43016, United States
  • KGL Skin Study Center, LLC /ID# 229253
    Newtown Square, Pennsylvania 19073-2228, United States
  • Nashville Center for Laser and Facial Surgery /ID# 229237
    Nashville, Tennessee 37203-1513, United States
  • Dallas Plastic Surgery Institute /ID# 229258
    Dallas, Texas 75231, United States
  • SkinDC /ID# 229251
    Arlington, Virginia 22209, United States
  • Premier Clinical Research /ID# 229261
    Spokane, Washington 99202, United States
  • Humphrey Cosmetic Dermatology /ID# 229522
    Vancouver, British Columbia V5Z 4E1, Canada
  • Dermetics Cosmetic Dermatology /ID# 229482
    Burlington, Ontario L7N 3N2, Canada
  • Dr Melinda Gooderham Medicine Profession /ID# 229456
    Cobourg, Ontario K9A 0Z4, Canada
  • The Center For Dermatology /ID# 229481
    Richmond Hill, Ontario L4B 1A5, Canada
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2022, 17 months.

Results were first posted in Nov 2024, 1 year 11 months after primary completion. A results delay was requested in Nov 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2021
First posted
Jul 2, 2021
StartActual
Jul 8, 2021
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Results delay requested
Nov 30, 2023
Results first posted
Nov 20, 2024
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04949399
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Jul 8, 2021
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Results posted
Nov 20, 2024
Last update
Nov 20, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion